MX2020003088A - Composicion medicinal que comprende el inhibidor del sglt2 y el antagonista del receptor de angiotensina. - Google Patents

Composicion medicinal que comprende el inhibidor del sglt2 y el antagonista del receptor de angiotensina.

Info

Publication number
MX2020003088A
MX2020003088A MX2020003088A MX2020003088A MX2020003088A MX 2020003088 A MX2020003088 A MX 2020003088A MX 2020003088 A MX2020003088 A MX 2020003088A MX 2020003088 A MX2020003088 A MX 2020003088A MX 2020003088 A MX2020003088 A MX 2020003088A
Authority
MX
Mexico
Prior art keywords
sglt
inhibitor
medicinal composition
receptor blocker
angiotensin receptor
Prior art date
Application number
MX2020003088A
Other languages
English (en)
Inventor
Tae Hun Kim
Original Assignee
Autotelic Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autotelic Bio Inc filed Critical Autotelic Bio Inc
Publication of MX2020003088A publication Critical patent/MX2020003088A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Se provee una composición farmacéutica que comprende un agente antidiabético y un agente antihipertensivo como ingredientes activos.
MX2020003088A 2017-09-19 2018-08-31 Composicion medicinal que comprende el inhibidor del sglt2 y el antagonista del receptor de angiotensina. MX2020003088A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170120311 2017-09-19
KR1020180075025A KR101943382B1 (ko) 2017-09-19 2018-06-28 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물
PCT/KR2018/010110 WO2019059557A2 (ko) 2017-09-19 2018-08-31 Sglt-2 저해제 및 안지오텐신 수용체 차단제를 포함하는 의약 조성물

Publications (1)

Publication Number Publication Date
MX2020003088A true MX2020003088A (es) 2020-08-17

Family

ID=65323033

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003088A MX2020003088A (es) 2017-09-19 2018-08-31 Composicion medicinal que comprende el inhibidor del sglt2 y el antagonista del receptor de angiotensina.

Country Status (7)

Country Link
US (1) US10980822B2 (es)
JP (1) JP6993502B2 (es)
KR (1) KR101943382B1 (es)
CN (1) CN110520133A (es)
BR (1) BR112020004107A2 (es)
MX (1) MX2020003088A (es)
WO (1) WO2019059557A2 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3105626A1 (en) 2018-07-19 2020-01-23 Astrazeneca Ab Methods of treating hfpef employing dapagliflozin and compositions comprising the same
BR112020008705A2 (pt) 2019-08-30 2022-03-22 Astrazeneca Ab Métodos de tratamento da insuficiência cardíaca com fração de ejeção reduzida com dapagliflozina
EP4114365A1 (en) * 2020-03-05 2023-01-11 KRKA, d.d., Novo mesto Pharmaceutical composition comprising sglt2 inhibitor
KR20230057388A (ko) * 2020-08-17 2023-04-28 티엔진 크레아트론 바이오테크놀로지 컴파니 리미티드 Sglt-2 억제제와 안지오텐신 수용체 길항제의 조성물 및 이의 용도
CN115894454A (zh) * 2021-09-06 2023-04-04 天地恒一制药股份有限公司 坎地沙坦的复合物，及其制备方法与应用
KR20230061281A (ko) * 2021-10-27 2023-05-08 지용하 안지오텐신 수용체 차단제 및 sglt2 억제제를 포함하는 복합 조성물
KR20230091684A (ko) * 2021-12-16 2023-06-23 주식회사 종근당 다파글리플로진과 시타글립틴을 포함하며, 정제사이즈 축소를 통해 복용편의성이 향상된 약제학적 복합제제 및 이의 제조방법

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6515117B2 (en) 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
AU2003248861B2 (en) 2002-07-09 2009-01-22 Bristol-Myers Squibb Company Substituted heterocyclic derivatives useful as antidiabetic and antiobesity agents and method
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
KR100888131B1 (ko) 2006-10-10 2009-03-11 한올제약주식회사 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제
CL2008003653A1 (es) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica.
JP2012176920A (ja) 2011-02-28 2012-09-13 Kowa Co 医薬組成物
SG11201501510SA (en) * 2012-08-30 2015-04-29 Taisho Pharmaceutical Co Ltd Combinations of sglt2 inhibitors and antihypertensive drugs
RU2016143092A (ru) 2014-04-04 2018-05-08 Санофи Замещенные соединения инданона в качестве модуляторов gpr119 для лечения диабета, ожирения, дислипидемии и связанных с ними нарушений
EA033821B1 (ru) 2015-06-04 2019-11-29 Ospedale San Raffaele Srl Применение ингибитора оси igfbp3/tmem219 для лечения диабета

Also Published As

Publication number Publication date
WO2019059557A3 (ko) 2019-05-09
US10980822B2 (en) 2021-04-20
WO2019059557A2 (ko) 2019-03-28
BR112020004107A2 (pt) 2020-09-24
RU2020113679A3 (es) 2021-10-20
JP6993502B2 (ja) 2022-01-13
US20200054656A1 (en) 2020-02-20
KR101943382B1 (ko) 2019-01-29
RU2020113679A (ru) 2021-10-20
JP2020534347A (ja) 2020-11-26
CN110520133A (zh) 2019-11-29

Similar Documents

Publication Publication Date Title
MX2020003088A (es) Composicion medicinal que comprende el inhibidor del sglt2 y el antagonista del receptor de angiotensina.
EP3891149A4 (en) RET INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
IL279036A (en) Pharmaceutical combination, the composition and preparation of a combination containing an activator of glucokinase and an inhibitor of SGLT-2, preparation methods and their uses
MX2017010858A (es) Composicion para el tratamiento de enfermedades relacionadas con la interleucina 6.
MX2015016254A (es) Forma de dosificacion resistente al uso indebido con perfil de liberacion bimodal.
PH12020550745A1 (en) Combination of a 4-pyrimidinesulfamide derivative with an sglt-2 inhibitor for the treatment of endothelin related diseases
SG11202104686QA (en) Ret inhibitors, pharmaceutical compositions and uses thereof
MX2020004071A (es) Derivados de aztreonam y usos de los mismos.
MX2020005483A (es) Antagonistas de ildr2 y combinaciones de los mismos.
PH12020550815A1 (en) Delayed release deferiprone tablets and methods of using the same
NI201300106A (es) Composición farmacéutica antihipertensiva
MX2016013431A (es) Composiciones farmaceuticas que comprenden agentes antibacterianos.
GEP20197020B (en) Vortioxetine pyroglutamate
EP3770148A4 (en) RECEPTOR INHIBITOR, PHARMACEUTICAL COMPOSITION INCLUDING IT AND ITS USE
AU2015303724B2 (en) Quinazoline derivative
PH12016501733A1 (en) Pharmaceutical composition for preventing or treating skin rash
MX2016008406A (es) Preparacion farmaceutica combinada que comprende el bloqueante del receptor de la angiotensina ii y el inhibidor de la hmg-coa reductasa.
EP3950677A4 (en) QUINOLYL CONTAINING COMPOUND AND PHARMACEUTICAL COMPOSITION AND THEIR USE
PH12015501036A1 (en) A pharmaceutical composition containing an ace inhibitor and a calcium channel blocker
CL2015003434A1 (es) Composición farmacéutica, su uso y régimen de administración para contracepción a demanda.
MX2021001043A (es) Composiciones para el tratamiento de hipertension.
IN2013MU03370A (es)
IN2013MU03422A (es)
WO2020101596A3 (en) A capsule composition comprising sunitinib
IN2014MU00859A (es)